- Previous Close
0.6100 - Open
0.6100 - Bid --
- Ask --
- Day's Range
0.6030 - 0.6700 - 52 Week Range
0.6030 - 18.0000 - Volume
39,414 - Avg. Volume
7,967 - Market Cap (intraday)
861,894 - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-100.0000 - Earnings Date Sep 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
www.oxurion.comRecent News: OXUR.BR
View MorePerformance Overview: OXUR.BR
Trailing total returns as of 9/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OXUR.BR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OXUR.BR
View MoreValuation Measures
Market Cap
935.38k
Enterprise Value
11.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.38
Price/Book (mrq)
--
Enterprise Value/Revenue
44.09
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-80.77%
Return on Equity (ttm)
--
Revenue (ttm)
263k
Net Income Avi to Common (ttm)
-18.97M
Diluted EPS (ttm)
-100.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
1.67M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.69M